The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma-Reference-Cited by-同舟云学术

The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma

Published:2017-04 Issue: Volume:55 Page:23-32
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Burwick Nicholas,Zhang Michael Y.,de la Puente Pilar,Azab Abdel Kareem,Hyun Teresa S.,Ruiz-Gutierrez Melisa,Sanchez-Bonilla Marilyn,Nakamura Tomoka,Delrow Jeffrey J.,MacKay Vivian L.,Shimamura Akiko

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference44 articles.

1. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the eastern cooperative oncology group;Rajkumar;J. Clin. Oncol.,2006

2. Primary dexamethasone treatment of multiple myeloma;Alexanian;Blood,1992

3. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma;Richardson;N. Engl. J. Med.,2005

4. A variant glucocorticoid receptor messenger RNA is expressed in multiple myeloma patients;Krett;Cancer Res.,1995

5. Hsp27 inhibits release of mitochondrial protein smac in multiple myeloma cells and confers dexamethasone resistance;Chauhan;Blood,2003

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hemin binding causes structural rearrangements in HRI to inhibit activation via autophosphorylation;2024-08-14

2. Inhibition of Acyl-CoA Synthetase Long Chain Isozymes Decreases Multiple Myeloma Cell Proliferation and Causes Mitochondrial Dysfunction;2024-03-14

3. Integrated Stress Response (ISR) Pathway: Unraveling Its Role in Cellular Senescence;International Journal of Molecular Sciences;2023-12-13

4. Pharmacologic activation of a compensatory integrated stress response kinase promotes mitochondrial remodeling in PERK-deficient cells;Cell Chemical Biology;2023-12

5. Hydrogen sulfide ameliorates abdominal aorta coarctation-induced myocardial fibrosis by inhibiting pyroptosis through regulating eukaryotic translation initiation factor 2α phosphorylation and activating PI3K/AKT1 pathway;The Korean Journal of Physiology & Pharmacology;2023-07-01